Shirley Ryan Abilitylab, Chicago, Illinois.
Dell Seton Medical Center, Austin, Texas.
Pharmacotherapy. 2019 Mar;39(3):253-260. doi: 10.1002/phar.2171. Epub 2018 Oct 3.
This study was conducted to describe the prevalence, epidemiology, and clinical outcomes of multidrug-resistant (MDR) organism (MDRO) pneumonia in critically ill patients.
A multicenter, prospective, observational study of patients admitted to 60 intensive care units (ICUs), from 34 hospitals, in the United States from November to December 2016. Adults (> 18 yrs) receiving antimicrobial therapy at least 5 days for pneumonia were included. Patients were classified into two categories, with or without MDRO, and subcategorized by pneumonia type.
Demographics, medication histories, and health care exposure were collected during ICU admission and compared using t test and chi-square tests. Multivariate logistic regression was used to determine predictive factors for MDRO pneumonia and hospital mortality. Of 652 patients, 92 patients (14.1%) developed MDR pneumonia. Predictors of MDRO pneumonia were acid suppression therapy within the previous 90 days (odds ratio [OR] 1.88 [1.14-3.09]; p=0.013), mechanical ventilation (OR 1.96 [1.14-3.35]; p<0.001), and history of MDRO infection (OR 4.74 [2.21-10.18]; p<0.001). Appropriate initial antimicrobial selection occurred in 58 patients (63%) with MDRO pneumonia compared to 464 patients (82.7%) in patients without MDRO pneumonia (p<0.001). MDRO pneumonia was not associated with hospital mortality (18.5% vs 17.6%, p=0.087).
In a broad cohort of critically ill patients, MDRO pneumonia is infrequent, and associated with factors describing the intensity of health care provided. Presence of MDRO pneumonia is not associated with hospital mortality. Further study is needed to clarify risk factors for multidrug-resistant pneumonia in critically ill patients.
本研究旨在描述重症患者中多重耐药(MDRO)菌肺炎的流行情况、流行病学和临床结局。
这是一项多中心、前瞻性、观察性研究,纳入了 2016 年 11 月至 12 月期间美国 34 家医院的 60 个重症监护病房(ICU)收治的至少接受 5 天抗菌治疗的肺炎患者。患者分为 MDRO 组和非 MDRO 组,并根据肺炎类型进行亚组分类。
在 ICU 入院时收集患者的人口统计学、用药史和医疗保健暴露情况,并使用 t 检验和卡方检验进行比较。采用多变量逻辑回归分析确定 MDRO 肺炎和医院死亡率的预测因素。在 652 名患者中,92 名(14.1%)患者发生 MDRO 肺炎。MDRO 肺炎的预测因素包括 90 天内使用胃酸抑制治疗(比值比 [OR] 1.88 [1.14-3.09];p=0.013)、机械通气(OR 1.96 [1.14-3.35];p<0.001)和 MDRO 感染史(OR 4.74 [2.21-10.18];p<0.001)。与非 MDRO 肺炎患者(82.7%)相比,92 名 MDRO 肺炎患者中有 58 名(63%)患者初始抗菌治疗选择恰当(p<0.001)。MDRO 肺炎与医院死亡率无关(18.5% vs 17.6%,p=0.087)。
在广泛的重症患者队列中,MDRO 肺炎并不常见,与描述医疗保健强度的因素相关。MDRO 肺炎的存在与医院死亡率无关。需要进一步研究来阐明重症患者多重耐药性肺炎的危险因素。